NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 62 resultados LastUpdate Última actualización 24/11/2017 [14:18:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


MULTILAMELLAR LIPID VESICLE COMPOSITIONS INCLUDING A CONJUGATED ANAPLASTIC LYMPHOMA KINASE (ALK) VARIANT AND USES THEREOF

NºPublicación: EP3244927A1 22/11/2017

Solicitante:
VEDANTRA PHARMACEUTICALS INC [US]

Resumen de: WO2016115480A1

The invention provides compositions including stabilized multilamellar lipid vesicles having crosslinked lipid bilayers (referred to herein as interbilayer-crosslinked multilamellar vesicles or ICMV) and including an ALK variant, pharmaceutical compositions containing vesicles (e.g., ICMV) including an ALK variant, and methods of treatment using such compositions. The invention provides compositions including stabilized multilamellar lipid vesicles with crosslinked lipid bilayers (e.g., an interbilayer-crosslinked multilamellar vesicle or ICMV) containing an Anaplastic lymphoma kinase (ALK) variant as an antigen that is associated with solid tumor cancers.



traducir


 

DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF 1-METHYL-1, 4-DIHYRDOINDENO1,2-CPYRAZOLE ANALOGUES AS POTENTIAL ANTICANER AGENTS TARGETING TUBULIN COLCHICINE BINDING SITE

NºPublicación: US2017327468A1 16/11/2017

Solicitante:
JOYOCHEM CO LTD [CN]

Resumen de: US2017327468A1

wherein R represents NH2 or NHOH; the invention also discloses a preparation method of the indenopyrazole compound, or pharmaceutical salts thereof. The compound of the present invention is an indenopyrazole small-molecule tubulin inhibitor having a novel structure, and has very strong proliferation inhibition activity to human hepatocellular carcinoma (HepG2) cells, human prostate carcinoma (PC3) cells, human cervical carcinoma (HeLa) cells, human breast adenocarcinoma (MCF-7) cells, and human leukemia (K562) cells; the compound is similar to colchicine in mechanism of action, and thus capable of inhibiting tubulin polymerization; the compound is significant for enhancing the specificity and effectiveness of drugs, reducing toxic and side effects, preventing drug tolerance, and so on.



traducir


 

METHODS OF TREATING MYELODYSPLASTIC SYNDROME WITH FARNESYLTRANSFERASE INHIBITORS

NºPublicación: WO2017196796A1 16/11/2017

Solicitante:
KURA ONCOLOGY INC [US]

Resumen de: WO2017196796A1

The present invention relates to the field of molecular biology, cell biology, and cancer biology. Specifically, the present invention relates to methods of treating myelodysplastic syndrome ("MDS") with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the Th1/Th2 balance and additional characteristics.



traducir


 

STABILIZED RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN COMPOSITIONS

NºPublicación: US2017326259A1 16/11/2017

Solicitante:
DAVE KAUSHIK J [US]
SHARMA SHUBH D [US]
ACTINIUM PHARMACEUTICALS INC [US]

Resumen de: US2017326259A1

Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.



traducir


 

METHODS OF TREATING MYELODYSPLASTIC SYNDROME WITH FARNESYLTRANSFERASE INHIBITORS

NºPublicación: US2017326133A1 16/11/2017

Solicitante:
KURA ONCOLOGY INC [US]

Resumen de: US2017326133A1

The present invention relates to the field of molecular biology, cell biology, and cancer biology. Specifically, the present invention relates to methods of treating myelodysplastic syndrome (“MDS”) with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the Th1/Th2 balance and additional characteristics.



traducir


 

SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOUR.

NºPublicación: WO2017193924A1 16/11/2017

Solicitante:
RUDONG RUIEN PHARMACEUTICAL TECH CO LTD [CN]

Resumen de: WO2017193924A1

Disclosed are the antibacterial activity and the antitumor activity of a class of new spiro three-membered ring and spiro five-membered ring containing peptide deformylase inhibitor. The spiro three-membered ring and spiro five-membered ring containing spiro peptide deformylase inhibitor of the present invention, as a class of new antibacterial agent, are effective against many antibiotic-resistant gram positive strains by inhibiting the activity of the peptide deformylase required in the synthesis of bacterial proteins, and do not affect the synthetic process of the main proteins of the human body, thus selectively killing bacteria. The spiro three-membered ring and spiro five-membered ring containing spiro peptide deformylase inhibitor of the present invention, as a class of new antibacterial agent, can affect the energy balance of the cells through inhibiting the peptide deformylase of the mitochondria in the cancer cells, so that the mitochondrial membrane depolarizes, ATP is exhausted and cell apoptosis is promoted, and has good inhibitory activities on many cancer cell strains such as colorectal cancer, leukemia, lung cancer, gastric cancer, cervical cancer, breast cancer, prostatic cancer, liver cancer and osteosarcoma at relatively lower concentrations.



traducir


 

ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH

NºPublicación: WO2017197240A1 16/11/2017

Solicitante:
UNIV MICHIGAN REGENTS [US]

Resumen de: WO2017197240A1

Provided herein are small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.



traducir


 

METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MULTIPLE MYELOMA USING NATURAL KILLER CELLS

NºPublicación: WO2017196657A1 16/11/2017

Solicitante:
ANTHROGENESIS CORP [US]
FISCHKOFF STEVEN ALAN [US]
HERZBERG URI [US]
KANG LIN [US]
MURPHY BRIAN [US]
NORDBERG ANDREA [US]
VOSKINARIAN-BERSE VANESSA [US]
WILSON KEITH [US]
ZHANG XIAOKUI [US]
MYINT HAN [US]
HUSSEIN MOHAMED [US]

Resumen de: WO2017196657A1

Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three- stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL- 2.



traducir


 

CBLB INHIBITION FOR TREATING FUNGAL INFECTIONS

NºPublicación: WO2017197243A1 16/11/2017

Solicitante:
OHIO STATE INNOVATION FOUNDATION [US]

Resumen de: WO2017197243A1

Disclosed herein is a method for treating a fungal infection in a subject that involves administering to the subject a composition comprising a therapeutically effective amount of a casitas B lymphoma-b (CBLB) inhibitor. Specifically, wherein the CBLB inhibitor is an siRNA. Further disclosed are specific nucleic acid sequences of siRNA CBLB inhibitors.



traducir


 

Combination of an anti-CD19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof

NºPublicación: AU2016266708A1 16/11/2017

Solicitante:
MORPHOSYS AG

Resumen de: AU2016266708A1

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.



traducir


 

SIALYLTRANSFERASE ST3GAL6 AS A MARKER FOR MULTIPLE MYELOMA

NºPublicación: US2017327899A1 16/11/2017

Solicitante:
NATIONAL UNIV OF IRELAND GALWAY [IE]

Resumen de: US2017327899A1

The present invention relates to the sialyltransferase ST3GAL6 for use as a biomarker for multiple myeloma, and especially as a marker for myelomas with inferior survival rates. The inventors have shown that glycosylation gene expression is dysregulated in Multiple Myeloma and that overexpression of the sialyltransferase ST3GAL6 is associated with inferior survival rates in patients.



traducir


 

HEMOPATHY PROGNOSIS METHOD

NºPublicación: US2017327896A1 16/11/2017

Solicitante:
CENTRE NATIONAL DE LA RECHERCHE SCIENT (CNRS) [FR]
UNIV FRANCOIS RABELAIS [FR]

Resumen de: US2017327896A1

This invention relates to an in vitro method for prognosis of the response to a chemotherapy of an individual suffering from chronic myeloid leukemia, comprising a. a step of measuring the expression level of at least one subgroup of genes chosen from a group of genes, b. a comparing step, and c. a step of determining a score S such that—if S is less than 1, said individual will have more than a 40% chance of responding to the chemotherapy, and—if S is greater than or equal to 1, said individual will have less than a 40% chance of responding to the chemotherapy.



traducir


 

BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA

NºPublicación: US2017327579A1 16/11/2017

Solicitante:
ENGMAB AG [CH]

Resumen de: US2017327579A1

A bispecific antibody specifically binding to the extracellular domain of human BCMA and human CD3ε, characterized in comprising a common antibody light chain is provided. Such bispecific antibody can be used as a medicament in the treatment of plasma cell disorders like Multiple Myeloma.



traducir


 

Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand

NºPublicación: US2017327591A1 16/11/2017

Solicitante:
SUCIU-FOCA NICOLE [US]
VLAD GEORGE [US]
CHANG CHIH-CHAO [US]
LIU ZHUORU [US]
COLOVAI ADRIANA IOANA [US]
THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK [US]

Resumen de: US2017327591A1

The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.



traducir


 

Anti-CD38 Antibodies for Treatment of Acute Lymphoblastic Leukemia

NºPublicación: US2017320961A1 09/11/2017

Solicitante:
JANSSEN BIOTECH INC [US]

Resumen de: US2017320961A1

The present invention relates to combination therapies with anti-CD38 antibodies.



traducir


 

METHODS FOR DIAGNOSING AND TREATING CD1D RESTRICTED GAMMA/DELTA T CELL LYMPHOMAS

NºPublicación: US2017320951A1 09/11/2017

Solicitante:
INSTITUT NATIONAL DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE (INSERM) [FR]
UNIVERSIT\u00C9 CLAUDE BERNARD LYON 1 [FR]
ECOLE NORMALE SUP\u00C9RIEURE DE LYON [FR]
CENTRE NATIONAL DE LA RECHERCHE SCIENT (CNRS) [FR]

Resumen de: US2017320951A1

Methods for diagnosing and treating CD1d-restricted gamma/delta T cell lymphomas are disclosed. In particular, the present disclosure relates to a method for diagnosing a T cell lymphoma as a CD1d-restricted gamma/delta T cell lymphoma in a patient in need thereof including i) detecting the presence of CD1d restricted gamma/delta T lymphoma cells in a cell lymphoma sample obtained from the patient and ii) concluding that the T cell lymphoma is a CD1d-restricted gamma/delta T cell lymphoma when the presence of CD1d restricted gamma/delta T cells is detected in the sample. The present disclosure also relates to a method for treating a CD1d-restricted gamma/delta T cell lymphoma as diagnosed by the diagnostic method, including administering the patient with a therapeutically effective amount of a CD1d antagonist.



traducir


 

Methods for Manipulating Phagocytosis Mediated by CD47

NºPublicación: US2017320945A1 09/11/2017

Solicitante:
UNIV LELAND STANFORD JUNIOR [US]

Resumen de: US2017320945A1

Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.



traducir


 

Combination of a CD30xCD16 antibody with a PD-1 antagonist for therapy

NºPublicación: AU2016257334A1 09/11/2017

Solicitante:
AFFIMED GMBH

Resumen de: AU2016257334A1

Described is a combination therapy of (i) a multifunctional antibody having specificity for CD30 and CD16A and (ii) an anti-PD-1 antibody for the treatment of a tumor, in particular Hodgkin lymphoma.



traducir


 

Treatment for multiple myeloma (MM)

NºPublicación: AU2016260895A1 09/11/2017

Solicitante:
MORPHOSYS AG

Resumen de: AU2016260895A1

The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.



traducir


 

ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

NºPublicación: US2017320944A1 09/11/2017

Solicitante:
SEATTLE GENETICS INC [US]

Resumen de: US2017320944A1

Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.



traducir


 

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML)

NºPublicación: WO2017191300A1 09/11/2017

Solicitante:
INSERM (INSTITUT NATIONAL DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE) [FR]
UNIVERSIT\u00C9 PAUL SABATIER TOULOUSE III [FR]
CENTRE HOSPITALIER UNIV DE TOULOUSE [FR]

Resumen de: WO2017191300A1

The present invention relates to pharmaceutical compositions for use in the treatment of chemoresistant acute myeloid leukemia (AML). The inventors have established a powerful preclinical model to screen in vivo responses to conventional genotoxics and to mimic the chemoresistance and minimal residual disease as observed in AML patients after chemotherapy. The inventors showed that cytarabine-resistance mechanism involves the CD39-dependent crosstalk between energetic niche and AML mitochondrial functions through CD39-P2Y13-cAMP-PKA signaling axis. In particular, the present invention relates to an inhibitor of the CD39-P2Y13-cAMP-PKA signaling axis for use in a method of treating chemoresistant acute myeloid leukemia (AML) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of said inhibitor.



traducir


 

QUINOLINE CARBOXAMIDES FOR USE IN THE TREATMENT OF LEUKEMIA

NºPublicación: US2017319568A1 09/11/2017

Solicitante:
ACTIVE BIOTECH AB [SE]

Resumen de: WO2016078921A1

A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of leukemia.



traducir


 

PAK1 INHIBITORS AND USES THEREOF

NºPublicación: WO2017192228A1 09/11/2017

Solicitante:
ALBERT EINSTEIN COLLEGE MEDICINE INC [US]

Resumen de: WO2017192228A1

Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using compounds that inhibit p21 protein (Cdc42/Rac)-activated kinase (PAKl).



traducir


 

3-Substituted Piperidine-2, 6-Diones and Non-Covalent Complexes with Albumin

NºPublicación: US2017319708A1 09/11/2017

Solicitante:
FL THERAPEUTICS LLC [US]

Resumen de: US2017319708A1

The present disclosure provides derivatives of 3-substituted piperidine-2,6-diones, non-covalently bound complexes with serum albumin, pharmaceutical compositions of the same, and methods of use thereof. The non-covalently bound complexes are significantly more water-soluble than the parent compounds, and are useful for the treatment of a cancer, such as multiple myeloma.



traducir


 

CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN BINDING DOMAINS TO THE T CELL RECEPTOR BETA CONSTANT REGION

Nº publicación: EP3241561A1 08/11/2017

Solicitante:
UCL BUSINESS PLC [GB]

Resumen de: EP3241561A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver